vs
Side-by-side financial comparison of Bio-Techne (TECH) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $221.4M, roughly 1.4× UNIVERSAL TECHNICAL INSTITUTE INC). Bio-Techne runs the higher net margin — 16.4% vs 0.2%, a 16.2% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (6.7% vs -1.5%). Over the past eight quarters, UNIVERSAL TECHNICAL INSTITUTE INC's revenue compounded faster (11.7% CAGR vs 1.3%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
TECH vs UTI — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $311.4M | $221.4M |
| Net Profit | $51.0M | $433.0K |
| Gross Margin | 66.9% | — |
| Operating Margin | 24.2% | 0.2% |
| Net Margin | 16.4% | 0.2% |
| Revenue YoY | -1.5% | 6.7% |
| Net Profit YoY | 126.0% | -60.5% |
| EPS (diluted) | $0.32 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.4M | $221.4M | ||
| Q4 25 | $295.9M | $220.8M | ||
| Q3 25 | — | $222.4M | ||
| Q2 25 | $317.0M | $204.3M | ||
| Q1 25 | $316.2M | $207.4M | ||
| Q4 24 | $297.0M | $201.4M | ||
| Q3 24 | $289.5M | $196.4M | ||
| Q2 24 | $306.1M | $177.5M |
| Q1 26 | $51.0M | $433.0K | ||
| Q4 25 | $38.0M | $12.8M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | $-17.7M | $10.7M | ||
| Q1 25 | $22.6M | $11.4M | ||
| Q4 24 | $34.9M | $22.2M | ||
| Q3 24 | $33.6M | $18.8M | ||
| Q2 24 | $40.6M | $5.0M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | 24.2% | 0.2% | ||
| Q4 25 | 18.4% | 7.1% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | -7.5% | 6.9% | ||
| Q1 25 | 12.2% | 8.1% | ||
| Q4 24 | 16.0% | 13.6% | ||
| Q3 24 | 13.8% | 13.3% | ||
| Q2 24 | 15.0% | 4.2% |
| Q1 26 | 16.4% | 0.2% | ||
| Q4 25 | 12.8% | 5.8% | ||
| Q3 25 | — | 8.4% | ||
| Q2 25 | -5.6% | 5.2% | ||
| Q1 25 | 7.1% | 5.5% | ||
| Q4 24 | 11.7% | 11.0% | ||
| Q3 24 | 11.6% | 9.6% | ||
| Q2 24 | 13.3% | 2.8% |
| Q1 26 | $0.32 | $0.01 | ||
| Q4 25 | $0.24 | $0.23 | ||
| Q3 25 | — | $0.33 | ||
| Q2 25 | $-0.11 | $0.19 | ||
| Q1 25 | $0.14 | $0.21 | ||
| Q4 24 | $0.22 | $0.40 | ||
| Q3 24 | $0.21 | $0.35 | ||
| Q2 24 | $0.26 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $209.8M | $162.0M |
| Total DebtLower is stronger | — | $127.8M |
| Stockholders' EquityBook value | $2.1B | $339.9M |
| Total Assets | $2.6B | $852.2M |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $209.8M | $162.0M | ||
| Q4 25 | $172.9M | $162.8M | ||
| Q3 25 | — | $169.1M | ||
| Q2 25 | $162.2M | $70.7M | ||
| Q1 25 | $140.7M | $96.0M | ||
| Q4 24 | $177.5M | $172.0M | ||
| Q3 24 | $187.5M | $161.9M | ||
| Q2 24 | $152.9M | $115.5M |
| Q1 26 | — | $127.8M | ||
| Q4 25 | $260.0M | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | $346.0M | $73.8M | ||
| Q1 25 | $330.0M | $94.4M | ||
| Q4 24 | $300.0M | $120.1M | ||
| Q3 24 | $300.0M | $125.7M | ||
| Q2 24 | $319.0M | $137.3M |
| Q1 26 | $2.1B | $339.9M | ||
| Q4 25 | $2.0B | $335.9M | ||
| Q3 25 | — | $328.1M | ||
| Q2 25 | $1.9B | $306.8M | ||
| Q1 25 | $2.0B | $293.9M | ||
| Q4 24 | $2.1B | $280.0M | ||
| Q3 24 | $2.1B | $260.2M | ||
| Q2 24 | $2.1B | $239.4M |
| Q1 26 | $2.6B | $852.2M | ||
| Q4 25 | $2.5B | $834.0M | ||
| Q3 25 | — | $826.1M | ||
| Q2 25 | $2.6B | $740.8M | ||
| Q1 25 | $2.6B | $720.4M | ||
| Q4 24 | $2.7B | $753.8M | ||
| Q3 24 | $2.7B | $744.6M | ||
| Q2 24 | $2.7B | $706.0M |
| Q1 26 | — | 0.38× | ||
| Q4 25 | 0.13× | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | 0.18× | 0.24× | ||
| Q1 25 | 0.16× | 0.32× | ||
| Q4 24 | 0.14× | 0.43× | ||
| Q3 24 | 0.14× | 0.48× | ||
| Q2 24 | 0.15× | 0.57× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 16.33× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $7.1M | ||
| Q4 25 | — | $3.1M | ||
| Q3 25 | — | $57.1M | ||
| Q2 25 | $98.2M | $18.1M | ||
| Q1 25 | $41.1M | $-789.0K | ||
| Q4 24 | $84.3M | $23.0M | ||
| Q3 24 | $63.9M | $67.5M | ||
| Q2 24 | $75.5M | $10.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-19.2M | ||
| Q3 25 | — | $40.6M | ||
| Q2 25 | $93.3M | $6.8M | ||
| Q1 25 | $31.0M | $-11.7M | ||
| Q4 24 | $77.5M | $19.6M | ||
| Q3 24 | $54.7M | $60.0M | ||
| Q2 24 | $57.5M | $3.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -8.7% | ||
| Q3 25 | — | 18.3% | ||
| Q2 25 | 29.4% | 3.4% | ||
| Q1 25 | 9.8% | -5.7% | ||
| Q4 24 | 26.1% | 9.7% | ||
| Q3 24 | 18.9% | 30.6% | ||
| Q2 24 | 18.8% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.1% | ||
| Q3 25 | — | 7.4% | ||
| Q2 25 | 1.5% | 5.5% | ||
| Q1 25 | 3.2% | 5.3% | ||
| Q4 24 | 2.3% | 1.7% | ||
| Q3 24 | 3.2% | 3.8% | ||
| Q2 24 | 5.9% | 4.0% |
| Q1 26 | — | 16.33× | ||
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | 1.82× | -0.07× | ||
| Q4 24 | 2.42× | 1.04× | ||
| Q3 24 | 1.90× | 3.58× | ||
| Q2 24 | 1.86× | 2.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
UTI
Segment breakdown not available.
